These results suggest that Benzo[a]pyrene may promote malignant progression of prostate cancer by upregulating PLK1 expression, and cryptotanshinone can antagonize the tumor-promoting effects induced by Benzo[a]pyrene. Here, PLK1 is linked to prostate carcinoma.